Recursion’s Phase 2 Trial Brings Hope for Cerebral Cavernous Malformation Treatment

Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX) has marked a significant milestone as its Phase 2 trial for the treatment of cerebral cavernous malformation continues to successfully enroll participants. The trial will investigate the effectiveness and safety of REC-994, an integrin-linked kinase inhibitor.

Cerebral cavernous malformation is a rare disease that causes abnormal blood vessels in the brain. The condition can result in seizures, headaches, and stroke, and there are currently no approved treatments. REC-994 has demonstrated promising results in preclinical studies, showing potential as a first-in-class treatment.

This makes the success of the trial even more important, as it brings hope to those suffering from this debilitating condition and is a significant step towards making this potential treatment a reality. As the trial progresses, the medical community will eagerly await the results, hoping for a breakthrough in the treatment of cerebral cavernous malformation.

About Recursion Pharmaceuticals

Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Share This Article

 

About the Author

Recursion’s Phase 2 Trial Brings Hope for Cerebral Cavernous Malformation Treatment

Editor Prism MarketView